iTeos Therapeutics, Inc.: cash and cash equivalents
Cash and cash equivalents for iTeos Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All iTeos Therapeutics, Inc. financial histories
What this measure means
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-12-31 to 2024-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2024-12-31 | 142,131,000 | USD | 2025-03-05 | 10-K · 0000950170-25-033066 |
| At date | 2023-12-31 | 251,177,000 | USD | 2025-03-05 | 10-K · 0000950170-25-033066 |
| At date | 2022-12-31 | 284,803,000 | USD | 2024-03-06 | 10-K · 0000950170-24-026866 |
| At date | 2021-12-31 | 848,537,000 | USD | 2023-03-15 | 10-K · 0000950170-23-007971 |
| At date | 2020-12-31 | 336,326,000 | USD | 2022-03-23 | 10-K · 0000950170-22-004409 |
| At date | 2019-12-31 | 19,868,000 | USD | 2021-03-24 | 10-K · 0001564590-21-015146 |
Related financial histories
- iTeos Therapeutics, Inc.: total assets
- iTeos Therapeutics, Inc.: total liabilities
- iTeos Therapeutics, Inc.: stockholders equity
- iTeos Therapeutics, Inc.: net income or loss
- iTeos Therapeutics, Inc.: operating cash flow
- iTeos Therapeutics, Inc.: capital expenditure payments
- iTeos Therapeutics, Inc.: revenue
- iTeos Therapeutics, Inc.: financing cash flow
- iTeos Therapeutics, Inc.: investing cash flow
- iTeos Therapeutics, Inc.: retained earnings or deficit
- iTeos Therapeutics, Inc.: basic weighted-average shares
- iTeos Therapeutics, Inc.: diluted weighted-average shares
- iTeos Therapeutics, Inc.: basic earnings per share
- iTeos Therapeutics, Inc.: diluted earnings per share
- iTeos Therapeutics, Inc.: income tax expense or benefit
- iTeos Therapeutics, Inc.: net property, plant and equipment
- iTeos Therapeutics, Inc.: share-based compensation expense
- iTeos Therapeutics, Inc.: operating income or loss
- iTeos Therapeutics, Inc.: current assets
- iTeos Therapeutics, Inc.: current liabilities
- iTeos Therapeutics, Inc.: current accounts payable
- iTeos Therapeutics, Inc.: operating expenses
- iTeos Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- iTeos Therapeutics, Inc. / CIK 0001808865
- Captured
- 2026-09-21T17:28:11.450Z
- SEC response SHA-256
f88106e2b35cb994ea1d777072397353d5f26b03465a85ed9dc9bec5789c50c6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001808865.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))